MC
ACHN

Moors & Cabot’s Achillion Pharmaceuticals ACHN Stock Holding History

Moors & Cabot’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,800
Closed -$91K – 561
2016
Q1 		$91K Buy
+11,800
New +$86.4K 0.02% 486

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Moors & Cabot's ACHN Position: Q2 2016 in Review

Moors & Cabot sold out of Achillion Pharmaceuticals (ACHN) in Q2 2016, closing a stake of 11,800 shares — an estimated $91K sold.

Moors & Cabot first reported a position in ACHN in Q1 2016 and held it in 1 quarter. The position peaked at $91K in Q1 2016. 147 funds tracked by Wall St. Rank hold ACHN as of Q2 2016.

  • Moors & Cabot reported no remaining Achillion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Moors & Cabot sold 11,800 Achillion Pharmaceuticals shares in Q2 2016, an estimated $91K.
  • Moors & Cabot first reported a position in Achillion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Moors & Cabot's Achillion Pharmaceuticals position peaked at $91K in Q1 2016.
  • 147 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2016.

Based on Moors & Cabot's 13F filing for Q2 2016, filed 8 Aug 2016.